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SUMMARY
Detection and quantification of Hb subtypes of human blood
is integral to presumptive identification of thalassaemias. It
has been used in neonatal screening of thalassaemia and Hb
variants. The use of discarded red blood cells following
processing of the cord blood for stem cells provides readily
available diagnostic material for thalassaemia screening. In
this study, we determined the range of Hb subtypes in 195
consecutive cord blood samples collected for cord blood
banking. The `cord blood samples’ analysed were those of
the remaining red blood cells after the cord blood was
processed for stem cell storage. Quantification of Hb
subtypes by high performance liquid chromatography (HPLC)
was done on BioRad Variant II Hb testing system. Only 73
(36.5%) of the samples could be analyzed neat without
dilution. With a 1:300 dilution with wash solution the
acceptable area as recommended by the manufacturer for
reading of a C-gram within the 1 to 3 million ranges were
achieved in all. Eighteen (9%) 12 showed classical Hb Barts
(γ4) prerun peaks were confirmed by Sebia Hydrasys
automated Hb gel electrophoresis and quantified by Sebia
Capillarys 2 capillary electrophoresis. Only 1 (0.5%) was
presumptively identified with HbH disease. Due to the
limited number of samples no beta-thalassaemia major, Hb E
beta-thalassaemia and Hb Barts hydrops fetalis were found.
The HPLC assay was possible at a cost US$ 5 per sample and
a turnover time of 10 samples per hour without technical
difficulties. This study reports an effective and valuable
protocol for thalassaemia screening in red blood cells which
would otherwise be discarded during cord blood processing.
Cord blood with severe and intermediate forms of
thalassaemia can be preselected and not stored.
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INTRODUCTION
The thalassaemias represent the most common autosomal
recessive disorders in the world. Thalassaemias are classified into
3 main clinical phenotypes: trait, intermedia and major. Beta-
thalassaemia major results from severe transfusion dependent
anaemia and alpha thalassaemia major or Hb Barts hydrops
foetalis is incompatible with life1. In Malaysia, 3.5-4.5% of
population are carriers of thalassaemia2. The thalassaemia trait is
usually asymptomatic with many carriers unaware of their status
in the absence of a blood test for screening.
After a baby is born, the umbilical cord is cut and most often
thrown away. However, it is a recognized fact that the
remaining blood in the cord is rich in stem cells which can be
collected. Cord blood is a source of `haemopoietic’ cells that
can be used in stem cell transplants to treat a range of diseases
and disorders. In cord blood banking, cord blood is processed
to separate the blood cells and collect the stem cells. These
stem cells are frozen and stored at minus 196 degrees Celsius.
Red blood cells separated out in the process are discarded.
Red cell indices
Neonatal blood cell indices show that the red blood cells are
larger than that of adults and at birth the mean corpuscular
volume (MCV) is 105-125 fl3.  In neonates, thalassaemia trait is
manifested by a decrease MCV (usually less than 95fl) compared
to normal infants4. In Hb Barts hydrops foetalis, numerous
nucleated red blood cells are seen in the peripheral blood smear.
Hb subtypes at birth
The haemoglobin composition in normal cord blood shows
the predominant Hb subtype is HbF (α2γ2) (60-85%) with
some HbA (α2β2)(15-40%) and no measurable HbA2 (α2δ2). Hb
Barts (γ4) is less than 0.5%. 
Beta-thalasssaemia
Adults who are carriers of classical beta-thalassaemia have
HbA2 levels that are elevated but this parameter is not useful
in the newborn for identification of carriers as no measurable
HbA2 is present. Lack of expression of one or both beta alleles
will result in reduced formation of HbA. HbA of <15% has
been used to identify beta-thalassaemia in newborn
screening5. In beta-thalassaemia intermedia, the predominant
Hb is Hb F and HbA is <15%. In beta-thalassaemia major
transfusion dependent with severe mutations (β0/β0) the cord
blood will show no HbA.
Alpha-thalassaemia
A relationship between Hb Barts levels in cord blood and
number of α-globin genes has been established,6,7,8,9,10. In Hb
Barts hydrops foetalis, the predominant Hb will be Hb Barts
and there will be no HbA present. The peripheral blood film
in Hb Barts hydrops foetalis, will show numerous nucleated
red blood cells. 
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International Standards of Cord Banking requires cord blood
units used for transplantation to exclude the presence of
hemoglobinopathy. The hemoglobinopathy of importance in
these countries being HbS11. In regions where thalassaemia is
a public health problem, there is a need to screen cord blood
that is to be stored for intermediate and severe forms of
thalassaemia. 
In this feasibility study, Hb subtypes were identified and
quantified in the discarded red blood cells in cord blood
banking for the presumptive screening of thalassaemia.
MATERIALS AND METHODS
Sample
One hundred ninety five consecutive cord blood units
collected in citrate-phosphate-dextrose (CPD) blood bags for
stem cell storage formed the study group. Each bag had 35ml
of CPD and a capacity to hold 250 ml of blood. Data of
volume of cord blood collected and complete blood counts
(CBC) were provided.  The CBC was determined by using an
automated blood count analyzer (CellDyn 3200, Abbott
Laboratories, USA) prior to cord blood processing. An aliquot
of 3.5ml of red blood cells separated out in the process of
stem cell collection from each of these cord blood units were
screened for thalassaemia following institutional clearance;
the study protocol was in agreement with local ethics
standards and the Helsinki Declaration of 1975, as revised in
1989. A schematic diagram for thalassemia screening  is
shown in Figure 1.
High Performance Liquid Chromatography (HPLC)
Quantification of Hb subtypes was performed using the
BioRad cation-exchange HPLC Hb analyser using the β-
thalassaemia short program and adhering to the
manufacturer’s instructions (BioRad Laboratories, Hercules,
USA). The instrument accurately measures HbA, HbF, HbA2
and Hb variants. Hb Barts and HbH appear as pre-run peaks in
the chromatogram (C-gram) with approximate retention time
(RT) values of 0.2 and 0.5 respectively. 
Capillary electrophoresis
Hb Barts was quantified by high voltage and resolution Hb
separation technique using the capillary electrophoresis
system (Sebia Capillarys 2, Sebia Inc, Georgia, USA).  HbA,
HbF and Hb Barts fractions were identified in zones 9, 7 and
12 respectively10.  
Automated Gel electrophoresis
Hb electrophoresis (Sebia Hydrasys, Sebia Inc., Georgia, USA)
at alkaline pH8.5 was done to confirm the presence of HbA,
HbF and Hb Barts. Hb Barts runs faster than HbA (5mm
anodal to HbA11.
RESULTS
Quantification of Hb subtypes on the BioRad Variant II Hb
testing system was only possible directly with 73 (36.5%)
samples. Dilution with wash solution in 1:300 (5μl blood /
1.5ml wash solution) showed that the area acceptable for
chromatography fell in the recommended 1 to 3 million
ranges in all samples. 
Thirty-nine (20%) of the 195 cord blood red cell samples had
MCV less than 105 fl. The mean MCV was 95.9fl.  Eighteen
(9.2%) of those with a MCV less than 105 fl had prerun peak
of Hb Barts (Table II) (Figure 2) (Figure 3). These were
confirmed by capillary electrophoresis and automated gel
electrophoresis. There was significant difference (p<0.05) in
the MCV and MCH of those with Hb Barts peaks and those
without. Twenty-one (10.7%) with MCV less than 105 fl and
no Hb Barts peak. This group was presumptively identified to
have other forms of thalassaemia.
There was a positive correlation of cord blood volume and Hb
levels (p<0.01, r=0.765) (Figure 4). There was no significant
difference in the haemoglobin levels in those with normal
MCV and those with thalassaemia (Table I). 
DISCUSSION
Fetal blood (umbilical vein) is only 50-60% saturated with
oxygen, and this relative hypoxia accounts for the magnitude
of active erythropoiesis observed in utero 3. At birth this is
manifested by a cord blood haemoglobin concentration of
14-22 g/dl, presence of nucleated red blood cells and
reticulocytosis (3-7%) and elevated erythropoietin levels. In
this study, the mean Hb seen was 10.2 gm/dl and there was a
positive correlation between the Hb levels and cord blood
volume indicating that haemodilution occurred from excess
CPD to blood ratio.
In the adult, screening for thalassaemia involves a step by
step process utilising the BHES protocol. B refers to a scrutiny
of the complete blood counts and an examination of the
blood film; H refers to HPLC to quantify Hb subtypes; E refers
to Hb electrophoresis and S refers to stability tests with the
most important of ones being the H-inclusion and Sickle cell
tests. Cutoff values to screen for thalassaemia being MCV less
than 80fl and MCH less than 27pg12,13,14. These values cannot
be used in cord blood screening for thalassaemia as the
normal neonate has a MCV of 105-125fl3.
Newborn screening methods for haemoglobinopathies
include alkaline electrophoresis, isoelectric focusing (IEF),
automated high performance liquid chromatography (HPLC)
and capillary electrophoresis (CE)15,16,17. The samples studied
were cord blood. In this study, discarded red cells derived
from cord blood processing for stem cells were screened for
severe and intermediate forms of thalassaemia. The use of
discarded red cells for screening of thalassaemia has not been
reported before.
In this study, thirty-nine (20%) have MCV less than 105fl and
were presumptively identified with thalassaemia. A
relationship between Hb Barts levels in cord blood and
number of α-globin genes has been established5,6,7,9,10. Hb Barts
was noted in eighteen (9%) and possible presence of alpha-
thalassaemia in 12 with levels >0.5 %. Studies suggest Hb
Barts less than 0.5% may be seen in normal neonates. One
sample showed Hb Barts level of 19.8% in keeping with the
possible presence of HbH disease. In mild alpha –thalassemia
mutations presenting as alpha thalassemia trait, Hb Barts
levels may not be detectable18.  Accurate identification of
Screening for Intermediate and Severe Forms of Thalassaemia in Discarded Red Blood Cells
Med J Malaysia Vol 66 No 5 December 2011 431
M
C
V
 >
 1
05
fl
 (
n
=
15
6)
M
C
V
 <
10
5 
fl
 (
n
=
39
)
P 
va
lu
e
Si
g
n
if
ic
an
ce
M
in
im
u
m
M
ax
im
u
m
M
ea
n
 ±
 2
SD
M
in
im
u
m
M
ax
im
u
m
M
ea
n
 ±
 2
 S
D
FB
C
H
b
5.
51
15
.2
0
10
.2
4 
±
 3
.4
83
6.
28
12
.2
0
9.
99
 ±
3.
13
2
.4
04
n
.s
.
M
C
V
10
5.
00
12
8.
00
11
2.
85
 ±
 1
0.
60
9
84
.8
0
10
4.
00
97
.3
6 
±
12
.5
32
.0
00
*
si
g
.
M
C
H
31
.7
0
46
.3
0
35
.5
3 
±
 3
.7
99
24
.5
0
38
.5
0
30
.8
7 
±
6.
99
9
.0
00
*
si
g
.
H
PL
C
H
b
F
55
.6
0
98
.7
0
84
.8
2 
±
 1
3.
98
4
69
.3
0
95
.2
0
82
.8
5 
±
 1
1.
90
9
.1
08
n
.s
.
H
b
A
3.
80
36
.3
0
15
.5
3 
±
 1
0.
39
6
0.
30
31
.1
0
17
.2
7 
±
 1
2.
27
4
.0
73
n
.s
.
*S
ig
. =
 P
 v
al
u
e 
<
 0
.0
1 
(A
n
al
ys
is
 w
as
 d
o
n
e 
u
si
n
g
 O
n
e 
w
ay
 A
n
o
va
 , 
SP
SS
 1
7)
  
n
.s
. =
 n
o
 s
ig
n
if
ic
an
ce
Ta
bl
e 
I: 
M
ea
n 
of
 H
b,
H
bF
, H
bA
, M
CV
 a
nd
 M
CH
  i
n 
19
5 
Co
rd
 b
lo
od
 s
am
pl
es
N
o
.
ra
ce
H
b
M
C
V
M
C
H
H
ig
h
 p
er
fo
rm
an
ce
 li
q
u
id
C
ap
ill
ar
y 
el
ec
tr
o
p
h
o
re
si
s
Se
b
ia
 h
yd
ra
sy
s
A
ss
u
m
ed
 
ch
ro
m
at
o
g
ra
p
h
y 
(H
PL
C
)
g
en
o
ty
p
e
H
b
 F
H
b
 A
H
b
 B
ar
ts
H
b
 F
H
b
 A
H
b
 B
ar
t
(Z
 1
2)
1.
25
37
1
C
9.
23
87
.0
24
.5
73
.5
28
.0
+
52
.2
25
.3
19
.8
+
- 
- 
/ -
 α
2.
25
45
8
C
7.
86
96
.0
28
.0
71
.4
25
.3
+
69
.2
25
.8
4.
3
+
- 
- 
/ α
α
3.
25
38
1
M
7.
79
93
.1
26
.9
86
.1
15
.6
+
82
.4
15
.7
1.
7
+
- 
α
/ α
α
3.
25
38
5
C
6.
28
93
.2
27
.1
75
.3
25
.5
+
73
.0
25
.4
1.
3
+
- 
α
/ α
α
4.
25
39
7
C
10
.1
87
.7
26
.9
85
.9
16
.0
+
84
.0
15
.1
0.
7
+
- 
α
/ α
α
5.
25
42
2
C
7.
58
95
.0
26
.5
76
.9
23
.6
+
74
.6
22
.5
2.
7
+
- 
α
/ α
α
7.
25
46
0
C
8.
21
91
26
.6
79
.7
16
.7
+
81
.8
16
.3
1.
9
+
- 
α
/ α
α
8.
25
46
1
C
11
.2
10
4
30
.0
90
.6
6.
9
+
90
.9
5.
7
3.
4
+
- 
α
/ α
α
9.
25
56
9
C
9.
70
87
.9
26
.1
73
.2
26
.3
+
71
.4
26
.9
1.
5
+
- 
α
/ α
α
10
.
25
60
1
C
12
.1
85
.3
27
.4
78
.8
21
.4
+
76
.8
19
.4
3.
4
+
- 
α
/ α
α
11
.
25
61
6
C
10
.7
88
.5
27
.4
77
.9
22
.1
+
77
.5
19
.0
3.
3
+
- 
α
/ α
α
12
.
25
62
7
C
8.
89
84
.8
26
.8
79
.9
19
.6
+
79
.4
17
.3
3.
1
+
- 
α
/ α
α
13
.
25
65
3
C
7.
79
89
.6
27
.1
78
.4
22
.4
+
76
.5
21
.1
2.
3
+
- 
α
/ α
α
14
.
25
36
5
C
10
.5
85
.8
27
.0
82
.1
18
.5
+
80
.1
19
.5
0.
4
+
α
α
/ α
α
15
.
25
43
5
C
9.
44
96
.1
29
.2
82
.2
16
.8
+
85
.3
14
.3
0.
3
+
α
α
/ α
α
16
.
25
56
5
C
10
.7
99
33
.2
87
.8
12
.3
+
88
.3
11
.7
0.
3
+
α
α
/ α
α
17
.
25
62
1
C
10
.8
10
1
32
.1
84
.3
15
.4
+
84
.5
15
.2
0.
3
+
α
α
/ α
α
18
.
25
65
9
C
8.
78
10
4
32
.9
82
.8
16
.3
+
82
.9
16
.1
0.
3
+
α
α
/ α
α
M
ea
n
92
.7
2
28
.0
9
80
.3
8
19
.3
7
78
.3
8
18
.4
6
2.
83
+
p
o
si
ti
ve
 [
H
PL
C
=
 p
re
ru
n
 p
ea
k;
 S
eb
ia
 h
yd
ra
sy
s=
 f
as
t 
ru
n
 b
an
d
] 
Se
b
ia
 C
ap
ill
ar
ys
 Z
-1
2=
zo
n
e 
12
; C
=
C
h
in
es
e;
 M
=
M
al
ay
Ta
bl
e 
II:
 C
or
d 
bl
oo
d 
sa
m
pl
es
 w
it
h 
H
b 
Ba
rt
s
Original Article
432 Med J Malaysia Vol 66 No 5 December 2011
Fig. 1: Schematic diagram for thalassaemia screening in cord
blood.
Fig. 2: C-gram of normal cord blood sample.
Fig. 3: C-gram of HbH disease with Hb Barts peak. Fig. 4: Scatter plot of cord blood volume and Hb level.
Fig. 5: C-gram of β-thalassaemia major. Fig. 6: C-gram of Hb Barts hydrops fetalis (newborn).
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alpha thalassemia carriers in newborns requires molecular
studies.  In cord blood banking it is the identification of HbH
disease that is of importance rather than carriers. 
The BioRad Variant II Hb analyzer demonstrates Hb Barts as a
prerun peak with a retention time of 0.2 in the
chromatogram. The Sebia Capillarys 2 system identifies Hb
Barts in zone 12 and quantifies it as a percentage. The
limitations of quantifying Hb Barts levels are due to the lack
of reference materials, controls or specific calibrators in the
current techniques. However the pattern of the
chromatogram generated by the BioRad Variant II Hb
analyzer (prerun peaks) and the high levels as seen in HbH
disease and Hb Barts hydrops fetalis  are able to presumptively
identify both these conditions. Current data on HbH disease
indicates this condition can result in morbidity and should be
identified17,18,19. Hb Barts hydrops fetalis is a fatal condition
and results in the death In-utero or within 6 hours of birth.
DNA studies in those infants whose cord blood showed Hb
Barts are necessary to confirm alpha-thalassaemia and
identify the number of α-globin genes affected in HbH
disease.
There were no cord blood samples in this study with beta-
thalassaemia major or Hb Barts hydrops foetalis. However we
were able in an earlier study to identify these severe
thalassaemia conditions easily by HPLC as they would show
total absence of HbA in both; in beta-thalassaemia major, the
predominant Hb is HbF with no HbA; in Hb Barts hydrops
foetalis Hb Barts is the predominant Hb and no HbA is
seen14,20,21 (Figure 5, Figure 6). In Hb E beta-thalassemia, there
will be measurable `HbA2‘. Normal neonates do not have
measurable HbA2 4,22,23,24. Any `HbA2’ seen in the
chromatogram is Hb E on the BioRad Variant II Hb analyzer
in the newborn (Figure 7). 
In this study, to quantify and identify Hb subtypes 3
instruments were used: BioRad Variant II Hb analyzer (HPLC),
Sebia Hydrasys (Hb electrophoresis) and Sebia Capillarys 2
(Hb capillary electrophoresis). The presumptive identification
of beta-thalassemia major, Hb E beta-thalassemia and Hb
Barts hydrops fetalis are easily done by HPLC. A prerun peak
of Hb Barts together with the presence of HbF and HbA in the
chromatogram warrants molecular analysis for HbH disease.
In cord blood banking, the identification of alpha or beta-
thalassemia carriers is not crucial.
CONCLUSION
A cutoff value of MCV less than 105fl presumptively
identifies thalassaemia in cord blood samples. This novel
approach using discarded red blood cells from cord blood has
the potential to identify Hb Barts hydrops fetalis, beta-
thalassemia major, Hb E beta-thalassemia and HbH disease.
Screening for thalassemia in discarded red cells available
following cord blood processing for stem cell storage is an
effective method to identify severe forms of thalassemia. In
countries where there is a high risk of thalassemia, it is
important to screen for severe and intermediate forms of
thalassemia prior to cord blood stem cells being stored. 
ACKNOWLEDGEMENT
We are grateful to the technical staff at the involved
institutions, Stem Life Bhd, Kuala Lumpur and Faculty of
Medicine and Health Sciences, Universiti Putra Malaysia. This
study was supported by a grant from the Ministry of Science,
Technology and Innovation (02-01-04-SF0876). 
REFERENCES
1. Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th Edition.
Blackwell Science, London. 2011.
2. George E. Editorial. Beta-thalassaemia major in Malaysia: an ongoing
public health problem. Medical J Malaysia 2001; 56: 397-400.
3. Alter BP. 1989. Methods in Hematology: Perinatal Hematology. Churchill
Livingstone, London. Chapter 6: Pp126-129.
4. Tritipsombut J, Sanchaisuriya K, Fuchoroen S, Fucharoen G,
Siriratmanawong N, Pinmaung-ngam C, Sanchaisuriya P, Dr. rer med.  Arch
Pathol Lab Med 2008; 132: 1739-45.
5. Mantikou E, Arkesteijn SG, Beckhoven van JM, Kerhoffs JL, Harteveld CL,
Giordano PC. A brief review on newborn screening methods for
hemoglobinopathies and preliminary results selecting beta thalassemia
carriers by quantitative estimation of the HbA fraction. Clinical
Biochemistry 2009; 42: 1780-5.
Fig. 7a:Cord Blood newborn. Fig. 7b: At age 8 months (HbE-βO thalassaemia).
Original Article
434 Med J Malaysia Vol 66 No 5 December 2011
6. George E, Selamah G. 1981. Hb Barts in cord blood studies in Malaysians.
Southeast Asian Journal of Tropical Medicine and Public Health 1981; 1:
87-9.
7. Lie-Injo LE, Solai A, Herrera AR, Nicolaisen L, Kan YW, Wan WP, Hassan K.
Hb Bart’s level in cord blood and deletions of the alpha-globin genes.
Blood 1982; 59(2): 370-76.
8. Zhao W, Zhang J, Wang N, Deng P. The relationship between Hb Barts
levels in cord blood and the deletions of α-globin genes. Hemoglobin
1988; 12(5): 519-27. 
9. van der Dijs FPL, Volmer M, van Gijssel-Wiersma DG, Smit JW, van Veen
R, Muskiet FAJ. Predictive value of cord blood hematological indices and
hemoglobin Barts for the detection of heterozygous α-thalassemia-2 in an
African-Caribbean population. Clinical Chemistry 1999; 45(9): 1495-500. 
10. Rugless MJ, Fisher CA, Stephens AD, Amos RJ, Mohammed T, Old JM. Hb
Bart’s in cord blood: an accurate indicator of alpha-thalassemia.
Hemoglobin 2006; 30(1): 57-62.
11. NetCord-FACT International Standards fotr Cord Blood Collection,
Processing, Testing Banking and Release; third edition, 2006.
12. Guideline. The laboratory diagnosis of haemoglobinopathies. Working
Party of the General Haematology Task Force of the British Committee for
Standards in Haematology. British Journal of Haematology 1998; 101: 783-
92.
13. George E, Khoo SK, Mokhtar AB, Nor Aini U. 2005. Screening for
thalassaemia in pregnant women: A laboratory perspective. Malaysian
Journal of Medicine and Health Sciences 2005; 1(2): 111-7.
14. George E, Zubaidah Z, Chin YM, Faridah M, Sapiah R. Identifying Hb
variants in Malaysia using agarose gel map. Malaysian J of Clinical
Chemistry 2010; 5(1): 33-7.
15. Winichagoon P, Sriphanich R, Saengow B, Chowthaworn J, Tantisrin P,
Kanokpongskdi S, Fucharoen S, Wasi P. Automated HPLC in prenatal
diagnosis of thalassemia. Laboratory Hematology 2002; 8: 29-35.
16. Hataichanok S, Goonapa F, Nattaya SU, Kanokwan S, Thawalwong R,
Supan F. Analysis of fetal blood using capillary electrophoresis system: A
simple method for prenatal diagnosis of severe thalassemia diseases.
European Journal of Haematology 2009; 83(1): 57-65. 
17. Charoenkwan P, Taweephol R, Sirichotiyakul SI, Tantiprabha W, Sae-Tung
R, Suanta S, Sakdasirisathaporn P, Sanguansermsri T. Cord blood screening
for α-thalassemia and hemoglobin variants by isoelectric focusing in
northern thai neonates: Correlation with genotypes and hematologic
parameters. Blood Cells, Molecules, and Diseases 2010; 45(1): 53-7. 
18. Kyriacou K, Kyrri A, Kalogirou E, Vasillades P, Angastiniotis M, Ioannou PA,
Kleanthous M. Hb Bart’s levels in cord blood and alpha-thalassemia
mutations in Cyprus. Hemoglobin 2000; 3: 171-80.
19. Chui DHK, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a
benign disorder. Blood 2003; 101(3): 791-99. 
20. Benz EJ. Newborn screening for α-Thalassemia-keeping up with
globalization. New England Journal of Medicine  2011; 364(8): 770-1. 
21. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP.
Heterogeneity of hemoglobin H disease in childhood. New England
Journal of Medicine 2011; 364(8): 710-8.
22. Clarke GM, Higgins TN. Cation-exchange HPLC is the method of choice
for screen for thalassaemia including neonatal screening where is
mandated and for quantification of HbA2 and HbF concentration. Clinical
Chemistry 2000; 46(8): 1284-90.
23. Wadia MR, Phanasgaokar SP, Nadkarno AH, Surve RR, Gorakshakar AC,
Colah RB, Mohanty D. Usefulness of automated chromatography for rapid
fetal blood analysis for second trimester prenatal diagnosis of
β‐thalassemia. Prenatal Diagnosis 2002; 22(2): 153-7.
24. Bain BJ, Wild BJ, Stephens AD, Phelan L. Variant Haemoglobin, A guide of
identification. 1st edition. Wiley-Blackwell. United Kingdom. Chapter 3:
pp 30. 2010.
